Melanoma: open trials in Portugal

• NCT07221734

  Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

  Trial Treatment · Phase 3 · mAbxience Research S.L.

  Funchal · Lisbon · Lisbon

  Registry updated 2026-10-29

• NCT06330064

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  Trial Treatment · Phase 1/2 · Daiichi Sankyo

  Champalimaud Clinical Centre, Lisbon · Unidade Local De Saude De Santa Maria E.P.E., Lisbon · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto · Unidade Local De Saude De Santo Antonio E.P.E., Porto

  Registry updated 2026-10-26

• NCT06697301

  Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

  Trial Treatment · Phase 2/3 · Eikon Therapeutics

  Instituto Portugues De Oncologia De Coimbra Francisco Gentil E.P.E., Coimbra · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Hospital da Luz, S.A, Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto

  Registry updated 2026-10-06

• NCT06961006

  A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

  Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC

  Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 4001), Lisbon · Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 4002), Lisbon · Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 4000), Porto

  Registry updated 2026-09-28

• NCT02332668

  A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC

  Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto

  Registry updated 2026-07-06

• 2025-521562-95-00

  Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)

  Trial Treatment · Phase 3 · Mabxience Research S.L.

  Servico de Saude da Regiao Autonoma Da Madeira EPERAM, Funchal · Champalimaud Clinical Centre, Lisbon · Hospital Cuf Descobertas S.A., Lisbon

  Registry updated 2026-06-04

• NCT06112314

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  Trial Treatment · Phase 3 · Immunocore Ltd

  Centro Hospitalar e Universitario de Coimbra EPE (CHUC), Coimbra · Hospital Lusiadas Lisboa (HPP Hospital Dos Lusiadas), Lisbon · Instituto Portugues de Oncologio de Lisboa Francisco Gentil EPE (IPO Lisboa) (IPOLFG), Lisbon

  Registry updated 2026-02-25

All Melanoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error